SEC Form 4

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	
--	--

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					2. Issuer Name and Ticker or Trading Symbol <u>Denali Therapeutics Inc.</u> [DNLI]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify					vner		
				3. Date of Earliest Transaction (Month/Day/Year) 12/12/2017								below)	ive uue		below)	specity			
(Street) CHICAGO IL 60631					4. If Amendment, Date of Original Filed (Month/Day/Year)							6.	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person					ŕ	
(City) (State) (Zip)																			
1 Title of (it (l		Table I - Non-					quired,	Dis	-	-			y O	1	of	6.00	norohin	7. Nature of
1. The or s	Security (Inst	(r. 3)	D	ate	onth/Day/Year) if any (Month/Day/Year		Transaction Code (Instr.				(Instr. 3	ed (A) or str. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		6. Owners Form: Dire (D) or Indir (I) (Instr. 4)	Direct Indirect str. 4)	Indirect Beneficial Ownership (Instr. 4)	
									v	Amount		(A) or (D) Price			Transaction (Instr. 3 and	d 4)			
Common	Stock		Table II - D	12/12/			rities Aca		icn	10,756		A	(1)(2)		11,068	,749		D ⁽⁴⁾	
							, warrants												
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Deri Seci Acq Disp	umber of vative urities uired (A) or oosed of (D) tr. 3, 4 and	6. Date Exe Expiration (Month/Day	Date		Securi Deriva	Title and Amount of curities Underlying rivative Security str. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporte	<i>r</i> e es ally Ig d	10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Nu	iount or mber of ares			Transact (Instr. 4)			
Series A-1 Preferred Stock	(1)	12/12/2017		с			10,068,749	(1)		(1)	Comm Stocl		,068,7	49	\$0.00	0		D ⁽⁴⁾	
Series A-2 Preferred Stock	(2)	12/12/2017		С			375,000	(2)		(2)	Comm Stocl		375,00	0	\$0.00	0		D ⁽⁴⁾	
Series B-1 Preferred Stock	(3)	12/12/2017		С			312,500	(3)		(3)	Comm Stock		812,50	0	\$0.00	0		D ⁽⁴⁾	
1. Name and Address of Reporting Person* ARCH Venture Fund VIII, L.P.																			
(Last) (First) (Middle) C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025					=														
(Street) CHICAC	50	IL	60631			-													
(City)		(State)	(Zip)																
		Reporting Person [*] Partners VIII,																	
(Last) (First) (Middle) C/O ARCH VENTURE PARTNERS 8755 W. HIGGINS ROAD, SUITE 1025																			
(Street) CHICAC	GO	IL	60631																
(City)		(State)	(Zip)																
		Reporting Person* Partners VIII,																	

(Last)	(First)	(Middle)
--------	---------	----------

C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025									
(Street) CHICAGO	IL	60631							
(City)	(State)	(Zip)							
1. Name and Addr	ess of Reporting Perso L <u>KEITH</u>	n*							
(Last)	(First)	(Middle)							
C/O ARCH VI	C/O ARCH VENTURE PARTNERS VIII, LLC								
8755 W. HIGGINS ROAD, SUITE 1025									
(Street)									
CHICAGO	IL	60631							
(City)	(State)	(Zip)							
1. Name and Address of Reporting Person* BYBEE CLINTON									
(Last)	(First)	(Middle)							
C/O ARCH VI	ENTURE PARTNE	RS VIII, LLC							
8755 W. HIGGINS ROAD, SUITE 1025									
(Street)									
CHICAGO	IL	60631							
(City)	(State)	(Zip)							

Explanation of Responses:

1. The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

2. The Series A-2 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

3. The Series B-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

4. The shares are directly held by ARCH Venture Fund VIII, L.P. ("ARCH VIII"). ARCH Venture Partners VIII, L.P. (the "GPLP"), as the sole general partner of ARCH VIII, may be deemed to beneficially own cretain of the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VIII. The GPLP and GPLLC disclaim beneficial ownership of such shares except to the extent of any pecuniary interest therein. Keith Crandell and Clinton Bybee, as managing directors of GPLLC, may be deemed to beneficially own the shares held by ARCH VIII. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Remarks:

ARCH Venture Fund VIII, L.P. By: ARCH Venture Partners VIII, L.P., By: /s/ Mark McDonnell, Attorney-in-Fact	<u>12/12/2017</u>
ARCH Venture Partners VIII, LLC By: /s/ Mark McDonnell, Attorney-in-Fact	<u>12/12/2017</u>
ARCH Venture Partners VIII, L.P. By: ARCH Venture Partners VIII, LLC By: /s/ Mark McDonnell, Attorney-in-Fact	<u>12/12/2017</u>
<u>/s/ Mark McDonnell, as</u> <u>Attorney-in-Fact for Keith</u> <u>Crandell</u>	<u>12/12/2017</u>
<u>/s/ Mark McDonnell, as</u> <u>Attorney-in-Fact for Clinton</u> <u>Bybee</u>	<u>12/12/2017</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.